Framingham Study38:06
“And in that case was a Framingham study.”
The Peter Attia Drive
#402 ‒ NMR blood analysis: how heart disease risk, insulin resistance, inflammation, and mortality risk can be assessed from a single blood sample | Jim Otvos, Ph.D.
3 months ago
Products mentioned (5)
34:14
“have that effect. CTP inhibitors are one of them. Niacin, you know, HDL drugs of a different type. So triglyceride lowering automatically.”
Discussed
2:17:29
“And of course, these were all... They were all initially investigated because of the potential to create higher HDL cholesterol. And now we certainly know that HDL cholesterol is not the HDL biomarker of interest, and people were being fooled into thinking that would have benefit.”
Discussed
2:18:29
“So what I told you is true, especially with the most powerful CETP inhibitors. They reduce small HDLP by 10% or 20%. If you ignore what's going on in HDL and you only look at what's happening with ApoB and LDL, you think obicetrapib is a no-brainer, it's going to be positive.”
Discussed
1:19:15
“and we'll talk about, citrate, and the three branch chain amino acids. So leucine, isoleucine, and valine. So why don't you tell us the story of how you developed this score?”
Discussed
1:35:52
“And then we simply looked at all the other things that we had learned to measure. And we had just kind of started this activity. So branched chain amino acids, isoleucine, leucine, and valine, ketone bodies, plasma protein. I mentioned those two things because when you look individually at those things, ketone bodies and plasma protein, they have significant associations with mortality.”
Discussed
34:14
“have that effect. CTP inhibitors are one of them. Niacin, you know, HDL drugs of a different type. So triglyceride lowering automatically.”
Discussed
34:36
“like niacin, for example, because not only did that modestly raise HDL cholesterol and lower triglyceride, which were two good things seemingly, but it made the LDL particles bigger and it made the HDL particles bigger because there's also a similar argument about it.”
Discussed
35:02
“studies and, and this has been reproduced with, you know, the fibrates and, and, and, and other drugs. So. So Jim, what would you say to the person listening who, cause I hear this all the time, who says, Hey guys, I do have a high LDL cholesterol and, and even my LDL particle number is very high on my NMR test, but I'm very high on my LDL cholesterol.”
Discussed
2:13:20
“And one of the first things that stood out to me looking at the Broadway and Brooklyn trials, which were the phase three trials of Obicetrapib, were that the reductions in LDLP and LDLC were greater than the reductions in APOB, if memory serves correctly. What do you think is happening there?”
Discussed
0:00 / 2:25:14
▾
0:0010:0020:0030:0040:0050:001:00:001:10:001:20:001:30:001:40:001:50:002:00:002:10:002:20:00
0:002:25:14
▾
Studies cited in this episode (13)
As referenced on air, with the quote and the moment. Reported, not evaluated.
Diabetes Prevention Program1:02:51
“The study that shows it the best is one that unfortunately hasn't been published yet. It's in the Diabetes Prevention Program”
MESA (Multi-Ethnic Study of Atherosclerosis)1:21:47
“You mentioned MESA, multi-ethnic study of atherosclerosis. That's a NIH funded study that started in about 2000. It's had more than 20 years of follow-up now.”
Women's Health Study1:22:22
“Same thing from other very large studies, women's health study. Twenty-six thousand women at baseline in a study that's been followed up for many years.”
Framingham Offspring Study1:22:30
“Framingham offsprings.”
JUPITER Trial1:22:34
“all sorts of intervention trials, jupiter, et cetera.”
Diabetes Prevention Program1:22:40
“The diabetes prevention program... told us was not just that LPIR score goes down with lifestyle intervention and branched chain amino acids go down, which is all good thing, but that those things going down, the delta between where it started and where you got after the intervention, very powerfully predicts incident diabetes or the lessened diabetes risk.”
Duke University Cardiac Catheterization Study1:24:49
“So back to MVX, that's exactly what we did in this cardiac catheterization study at Duke University. 7,000 people over a period of years recruited into this biorepository.”
2023 MVX cardiac catheterization cohort paper1:43:28
“We've learned a lot since this 2023 first publication about MVX in this cardiac catheterization cohort. The important thing that we did there, I was advised that I really shouldn't try to publish this until we had replications.”
CathGen study (cardiac catheterization cohort in Utah, Salt Lake City)1:43:47
“Because these hazard ratios were so dramatically different from low and high MVX scores. So in that paper, we reported a completely independent cardiac cath population in Utah, Salt Lake City, and it replicated very well.”
Masl-D paper1:44:19
“The one that just came out, of course, was the Masl-D paper. Is that the one you wanted to chat about?”
EPIS study (study of older people)1:47:41
“And actually the one study that I was sort of confusing with the heart failure study is a study called EPIS. It's a study of older people with lots of things being measured, including these biological age, measures by chemistry assay, not the epigenetic flavors.”
MESA study (60-year-old people at entry)1:50:57
“So, the paper that appeared a couple months ago was from MESA. So, we've been talking about MESA, 60-year-old people at entry. They weeded out all the people in MESA that had any self-reported or otherwise diseases.”